Maryland State Retirement & Pension System Has $1.65 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Maryland State Retirement & Pension System lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 6,990 shares of the biopharmaceutical company’s stock after selling 203 shares during the period. Maryland State Retirement & Pension System’s holdings in Alnylam Pharmaceuticals were worth $1,645,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ALNY. Larson Financial Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $33,000. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $35,000. True Wealth Design LLC increased its stake in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $45,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 11.8 %

NASDAQ:ALNY opened at $283.34 on Friday. The stock’s fifty day moving average price is $257.16 and its two-hundred day moving average price is $259.65. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market cap of $36.68 billion, a price-to-earnings ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ALNY shares. Needham & Company LLC restated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday. Citigroup boosted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research note on Friday. Scotiabank boosted their price target on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research note on Friday. Finally, Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $310.22.

Insiders Place Their Bets

In other news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.